Hospital
Bronson Methodist Hospital
Bronson Methodist Hospital was paid $109.07M by Medicaid between Jan 2018 and Dec 2024, across 669 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 15% of everything it billed.
33Billing provider infoBRONSON METHODIST HOSPITAL
KALAMAZOO, MI 49007
KALAMAZOO, MI 49007
33aNPI1831116441assigned 07/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$109.07M
24GClaims3,911,759
24DCodes billed669
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#6 of 86
Median peer was paid$21.55M
This provider vs. median5.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official EAST, REBECCA controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 425,002 | $12.02M | |
| 2019 | 439,579 | $11.60M | |
| 2020 | 483,926 | $13.46M | |
| 2021 | 622,934 | $18.17M | |
| 2022 | 640,685 | $18.79M | |
| 2023 | 687,609 | $18.70M | |
| 2024incomplete | 612,024 | $16.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 15% | 279,477 | 242,109 | $15.97M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 50,044 | 45,523 | $9.77M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.2% | 74,725 | 67,324 | $8.99M |
| G0378 | Hospital observation service, per hour | 4.8% | 14,834 | 11,868 | $5.21M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 12,952 | 12,214 | $3.81M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 3.4% | 1,424 | 1,421 | $3.69M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 35,034 | 31,562 | $2.56M |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 2.2% | 2,327 | 2,206 | $2.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 27,166 | 25,655 | $2.18M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 62,266 | 22,142 | $1.82M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 34,280 | 32,697 | $1.70M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.3% | 80,895 | 78,000 | $1.38M |
657 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 80,890 | $1.38M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 10,007 | $1.36M |
| 59025 | Fetal non-stress test | 1.1% | 13,453 | $1.22M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 6,912 | $1.18M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.1% | 72,967 | $1.17M |
| G0379 | Direct admission of patient for hospital observation care | 1.0% | 3,033 | $1.12M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 13,615 | $1.10M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 1.0% | 339 | $1.09M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 14,958 | $1.08M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,336 | $1.05M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,928 | $991K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,790 | $899K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 32,603 | $889K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,572 | $780K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 708 | $675K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 29,006 | $672K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,007 | $641K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,810 | $630K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,751 | $609K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 17,967 | $602K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,528 | $598K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 4,474 | $581K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,708 | $577K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,488 | $576K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 1,665 | $576K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,797 | $574K |
| G0451 | Development testing, with interpretation and report, per standardized instrument form | <1% | 17,943 | $503K |
| 64721 | <1% | 602 | $484K | |
| 86900 | <1% | 13,962 | $466K | |
| 90378 | <1% | 310 | $438K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 63,694 | $436K |
| 80061 | Lipid panel | <1% | 48,138 | $432K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 38,665 | $428K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 10,611 | $428K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,950 | $418K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 31,067 | $405K |
| 36415 | Collection of venous blood by venipuncture | <1% | 219,291 | $394K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,722 | $371K |
| 80053 | Comprehensive metabolic panel | <1% | 138,057 | $367K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 9,004 | $358K |
| Q3014 | Telehealth originating site facility fee | <1% | 21,355 | $356K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 1,308 | $347K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,119 | $342K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 247 | $335K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 37,455 | $331K |
| 90677 | <1% | 3,220 | $321K | |
| 20610 | <1% | 2,311 | $317K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 33,390 | $313K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,633 | $307K |
| 76830 | Ultrasound, transvaginal | <1% | 5,749 | $303K |
| 76801 | <1% | 5,742 | $302K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 20,015 | $294K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,542 | $292K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,375 | $278K |
| 93304 | <1% | 1,037 | $277K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 19,125 | $274K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,947 | $273K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 171,729 | $269K |
| 47562 | <1% | 87 | $268K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 250 | $255K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 10,533 | $254K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,513 | $253K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 13,646 | $234K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,054 | $231K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,156 | $230K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13,254 | $230K |
| 97161 | <1% | 4,558 | $226K | |
| 95716 | <1% | 463 | $226K | |
| 87507 | <1% | 1,532 | $218K | |
| 72100 | <1% | 7,481 | $201K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,557 | $201K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,581 | $199K |
| 76770 | <1% | 3,608 | $193K | |
| 86003 | <1% | 3,907 | $190K | |
| 95819 | <1% | 1,397 | $188K | |
| 86780 | <1% | 24,860 | $187K | |
| 97162 | <1% | 3,897 | $184K | |
| 93975 | <1% | 1,809 | $177K | |
| 42830 | <1% | 113 | $169K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,801 | $168K |
| 96415 | <1% | 3,558 | $156K | |
| 58661 | <1% | 54 | $155K | |
| 80074 | <1% | 6,968 | $153K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 22,604 | $152K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 37,938 | $147K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,278 | $146K |
| 87150 | <1% | 9,363 | $140K | |
| 90686 | <1% | 9,703 | $134K | |
| 90651 | <1% | 1,663 | $134K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 43,711 | $133K |
| 93971 | <1% | 2,611 | $127K | |
| 94060 | <1% | 936 | $124K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 4,381 | $124K |
| 95951 | <1% | 328 | $122K | |
| 76642 | <1% | 2,959 | $113K | |
| 83013 | <1% | 3,878 | $113K | |
| 91320 | <1% | 1,036 | $111K | |
| 10060 | <1% | 1,408 | $109K | |
| 36430 | <1% | 663 | $107K | |
| 72141 | <1% | 978 | $105K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 8,319 | $105K |
| 90750 | <1% | 747 | $104K | |
| 97597 | <1% | 1,041 | $102K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 41,466 | $102K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 551 | $100K |
| 64615 | <1% | 732 | $99K | |
| 93017 | <1% | 2,628 | $96K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,318 | $95K |
| 74018 | <1% | 7,305 | $95K | |
| 86803 | <1% | 17,082 | $92K | |
| 92523 | <1% | 800 | $91K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 116 | $90K |
| 93308 | <1% | 731 | $89K | |
| 73110 | <1% | 5,993 | $87K | |
| 95816 | <1% | 668 | $84K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 168 | $84K |
| 76536 | <1% | 2,006 | $82K | |
| 74183 | <1% | 374 | $81K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,419 | $81K |
| 29075 | <1% | 593 | $79K | |
| 73030 | <1% | 5,914 | $77K | |
| 73610 | <1% | 6,500 | $76K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,126 | $76K |
| 95909 | <1% | 528 | $75K | |
| 82728 | <1% | 14,810 | $75K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 805 | $74K |
| 90678 | <1% | 251 | $71K | |
| 96367 | <1% | 2,365 | $70K | |
| 73130 | <1% | 6,530 | $70K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,624 | $69K |
| 71250 | <1% | 1,095 | $68K | |
| 58301 | <1% | 508 | $66K | |
| 73562 | <1% | 5,230 | $66K | |
| 84466 | <1% | 13,228 | $65K | |
| 84702 | <1% | 13,296 | $65K | |
| 86235 | <1% | 1,973 | $64K | |
| 73221 | <1% | 493 | $64K | |
| 93970 | <1% | 592 | $64K | |
| 95811 | <1% | 116 | $60K | |
| 58571 | <1% | 13 | $60K | |
| 90732 | <1% | 676 | $60K | |
| 87077 | <1% | 19,316 | $59K | |
| 73630 | <1% | 6,137 | $59K | |
| 74230 | <1% | 707 | $59K | |
| 97165 | <1% | 1,146 | $58K | |
| 90480 | <1% | 1,501 | $58K | |
| 84439 | <1% | 15,073 | $58K | |
| 73564 | <1% | 2,378 | $58K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 290 | $58K |
| 70491 | <1% | 603 | $58K | |
| S4005 | Interim labor facility global (labor occurring but not resulting in delivery) | <1% | 519 | $57K |
| 87081 | <1% | 18,040 | $56K | |
| 85027 | <1% | 23,006 | $56K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,576 | $54K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 914 | $53K |
| 97166 | <1% | 1,173 | $53K | |
| 82607 | <1% | 9,405 | $52K | |
| 70486 | <1% | 1,761 | $52K | |
| 87529 | <1% | 2,667 | $52K | |
| 87631 | <1% | 2,419 | $51K | |
| 73140 | <1% | 3,938 | $51K | |
| 72040 | <1% | 3,229 | $50K | |
| 87186 | <1% | 15,087 | $49K | |
| 88342 | <1% | 2,188 | $49K | |
| 87205 | <1% | 25,332 | $48K | |
| 70498 | <1% | 340 | $48K | |
| 87536 | <1% | 1,052 | $46K | |
| 92557 | <1% | 1,507 | $45K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 37,590 | $43K |
| 93225 | <1% | 1,200 | $43K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,347 | $43K |
| 87340 | <1% | 15,516 | $42K | |
| 96417 | <1% | 966 | $41K | |
| 95700 | <1% | 471 | $41K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,188 | $40K |
| 92587 | <1% | 369 | $40K | |
| 82274 | <1% | 4,601 | $40K | |
| 31575 | <1% | 408 | $40K | |
| 90474 | <1% | 5,030 | $39K | |
| 97116 | <1% | 3,163 | $39K | |
| 76886 | <1% | 920 | $39K | |
| 76882 | <1% | 946 | $39K | |
| 77065 | Tomosynthesis, mammo | <1% | 963 | $39K |
| 73560 | <1% | 2,285 | $38K | |
| 94726 | <1% | 1,247 | $38K | |
| 72158 | <1% | 211 | $38K | |
| 84403 | <1% | 3,061 | $37K | |
| 73502 | <1% | 3,232 | $36K | |
| 44970 | <1% | 12 | $35K | |
| 83880 | <1% | 5,306 | $35K | |
| 20611 | <1% | 344 | $35K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,810 | $35K |
| 83540 | <1% | 13,729 | $35K | |
| 83970 | <1% | 2,152 | $34K | |
| 97802 | <1% | 2,661 | $34K | |
| 95910 | <1% | 229 | $34K | |
| 92611 | <1% | 707 | $33K | |
| 87070 | <1% | 12,393 | $33K | |
| 83516 | <1% | 7,968 | $32K | |
| 0001A | <1% | 954 | $32K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 2,987 | $32K |
| 72082 | <1% | 945 | $32K | |
| 82670 | <1% | 2,479 | $32K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,644 | $31K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,379 | $31K |
| 81001 | <1% | 63,410 | $30K | |
| 90670 | <1% | 2,571 | $30K | |
| 97803 | <1% | 3,546 | $30K | |
| 96523 | <1% | 1,003 | $30K | |
| 82785 | <1% | 3,828 | $28K | |
| 0124A | <1% | 1,026 | $28K | |
| 96127 | <1% | 5,007 | $28K | |
| 0002A | <1% | 748 | $27K | |
| 82570 | <1% | 12,378 | $26K | |
| 86008 | <1% | 600 | $26K | |
| 96161 | <1% | 4,813 | $26K | |
| 84481 | <1% | 3,540 | $25K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,381 | $24K |
| 86376 | <1% | 3,793 | $23K | |
| 83001 | <1% | 2,812 | $23K | |
| 82043 | <1% | 8,472 | $23K | |
| 95806 | <1% | 359 | $23K | |
| 73070 | <1% | 1,712 | $23K | |
| 52000 | <1% | 97 | $23K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 86 | $23K |
| 86038 | <1% | 5,048 | $22K | |
| 64400 | <1% | 196 | $22K | |
| 64483 | <1% | 58 | $22K | |
| 82950 | <1% | 8,229 | $22K | |
| 76870 | <1% | 1,147 | $21K | |
| 85610 | <1% | 22,377 | $21K | |
| 86140 | <1% | 18,043 | $21K | |
| 73590 | <1% | 2,058 | $21K | |
| 84146 | <1% | 2,564 | $20K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 948 | $20K |
| 84484 | <1% | 22,884 | $20K | |
| 0054A | <1% | 660 | $20K | |
| 87563 | <1% | 1,161 | $20K | |
| 72110 | <1% | 760 | $20K | |
| Q5102 | Injection, infliximab, biosimilar, 10 mg | <1% | 29 | $20K |
| 81025 | <1% | 26,256 | $18K | |
| 80076 | <1% | 7,064 | $18K | |
| 84112 | <1% | 1,684 | $18K | |
| 86696 | <1% | 1,835 | $18K | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 512 | $17K |
| 82784 | <1% | 2,697 | $17K | |
| 86200 | <1% | 3,698 | $17K | |
| 83735 | <1% | 14,044 | $16K | |
| 16020 | <1% | 415 | $16K | |
| 90656 | <1% | 1,753 | $16K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 532 | $16K |
| 93226 | <1% | 461 | $16K | |
| 82746 | <1% | 3,067 | $16K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,350 | $16K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 20 | $16K |
| 58300 | <1% | 990 | $15K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 91 | $15K |
| 73090 | <1% | 2,051 | $15K | |
| 95782 | <1% | 28 | $14K | |
| 83002 | <1% | 1,622 | $13K | |
| 74022 | <1% | 1,055 | $13K | |
| 72072 | <1% | 435 | $13K | |
| 96411 | <1% | 325 | $13K | |
| 82951 | <1% | 1,786 | $13K | |
| 88304 | <1% | 3,993 | $13K | |
| 95911 | <1% | 49 | $13K | |
| 97163 | <1% | 270 | $13K | |
| 83014 | <1% | 3,775 | $13K | |
| 0004A | <1% | 410 | $13K | |
| 57454 | <1% | 83 | $13K | |
| 96416 | <1% | 72 | $13K | |
| 54150 | <1% | 13 | $12K | |
| 81003 | <1% | 26,484 | $12K | |
| 19083 | <1% | 13 | $12K | |
| 86695 | <1% | 1,834 | $12K | |
| 86706 | <1% | 2,683 | $12K | |
| 71271 | <1% | 205 | $11K | |
| 88307 | <1% | 1,910 | $11K | |
| 95800 | <1% | 204 | $11K | |
| 80069 | <1% | 3,123 | $11K | |
| 90620 | <1% | 397 | $11K | |
| 93660 | <1% | 42 | $11K | |
| 73552 | <1% | 820 | $11K | |
| 17250 | <1% | 266 | $11K | |
| 86769 | <1% | 324 | $11K | |
| 95908 | <1% | 73 | $11K | |
| 84153 | <1% | 1,421 | $11K | |
| 86160 | <1% | 1,803 | $10K | |
| 85652 | <1% | 15,574 | $10K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $10K |
| 90688 | <1% | 921 | $10K | |
| 92579 | <1% | 479 | $10K | |
| 77080 | <1% | 180 | $10K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 335 | $9K |
| 87220 | <1% | 8,648 | $9K | |
| 17110 | <1% | 441 | $9K | |
| 93880 | <1% | 90 | $9K | |
| 86225 | <1% | 2,112 | $9K | |
| 0071A | <1% | 286 | $9K | |
| 87486 | <1% | 1,332 | $9K | |
| 87581 | <1% | 1,332 | $9K | |
| 86039 | <1% | 2,137 | $9K | |
| 90675 | <1% | 51 | $9K | |
| 73080 | <1% | 1,181 | $9K | |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 38 | $9K |
| 82627 | <1% | 858 | $9K | |
| 71101 | <1% | 693 | $9K | |
| 20680 | <1% | 12 | $8K | |
| 0081A | <1% | 239 | $8K | |
| 76820 | <1% | 3,264 | $8K | |
| 72197 | <1% | 53 | $8K | |
| 83690 | <1% | 21,971 | $8K | |
| 90837 | Psychotherapy session, about an hour | <1% | 266 | $8K |
| 82565 | <1% | 4,016 | $8K | |
| 70496 | <1% | 428 | $7K | |
| 80164 | <1% | 1,616 | $7K | |
| 72156 | <1% | 55 | $7K | |
| 99496 | <1% | 136 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 107 | $7K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 808 | $7K |
| 0072A | <1% | 184 | $6K | |
| 58100 | <1% | 77 | $6K | |
| 84100 | <1% | 5,972 | $6K | |
| 82533 | <1% | 903 | $6K | |
| 82248 | <1% | 3,011 | $6K | |
| 93922 | <1% | 313 | $6K | |
| 87209 | <1% | 806 | $6K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,064 | $6K |
| 76881 | <1% | 107 | $5K | |
| 83525 | <1% | 1,048 | $5K | |
| 72050 | <1% | 192 | $5K | |
| 73000 | <1% | 436 | $5K | |
| 36591 | <1% | 222 | $5K | |
| 84703 | <1% | 4,373 | $5K | |
| 51702 | <1% | 145 | $5K | |
| 86431 | <1% | 2,573 | $5K | |
| 82247 | <1% | 2,070 | $5K | |
| 85730 | <1% | 6,734 | $5K | |
| 84156 | <1% | 4,640 | $5K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 18 | $5K |
| 72170 | <1% | 321 | $5K | |
| 69210 | <1% | 419 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,192 | $5K |
| 90662 | <1% | 237 | $5K | |
| 0082A | <1% | 121 | $5K | |
| 83020 | <1% | 1,342 | $4K | |
| 11982 | <1% | 51 | $4K | |
| 86665 | <1% | 737 | $4K | |
| 83615 | <1% | 3,753 | $4K | |
| 74019 | <1% | 396 | $4K | |
| 90716 | <1% | 1,544 | $4K | |
| 72070 | <1% | 291 | $4K | |
| 84550 | <1% | 2,923 | $4K | |
| 85046 | <1% | 4,152 | $4K | |
| 70360 | <1% | 240 | $4K | |
| 82550 | <1% | 3,192 | $4K | |
| 74174 | <1% | 26 | $4K | |
| 73660 | <1% | 353 | $4K | |
| 87641 | <1% | 1,191 | $4K | |
| 11981 | <1% | 91 | $4K | |
| 82952 | <1% | 1,768 | $4K | |
| 87328 | <1% | 728 | $4K | |
| 76825 | <1% | 13 | $4K | |
| 82977 | <1% | 1,456 | $4K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,060 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 163 | $3K |
| 20550 | <1% | 29 | $3K | |
| 87329 | <1% | 728 | $3K | |
| 0052A | <1% | 97 | $3K | |
| 29125 | <1% | 606 | $3K | |
| 87899 | <1% | 580 | $3K | |
| 86850 | <1% | 13,252 | $3K | |
| 86147 | <1% | 312 | $3K | |
| 51798 | <1% | 1,111 | $3K | |
| 0051A | <1% | 96 | $3K | |
| 84145 | <1% | 2,525 | $3K | |
| 86787 | <1% | 843 | $3K | |
| 86618 | <1% | 648 | $3K | |
| 84460 | <1% | 1,305 | $3K | |
| 83721 | <1% | 558 | $3K | |
| 72146 | <1% | 51 | $3K | |
| 85380 | <1% | 3,932 | $3K | |
| 87177 | <1% | 793 | $3K | |
| 84144 | <1% | 284 | $3K | |
| 84450 | <1% | 1,221 | $3K | |
| 80178 | <1% | 851 | $2K | |
| 0121A | <1% | 103 | $2K | |
| 31231 | <1% | 29 | $2K | |
| 82150 | <1% | 1,124 | $2K | |
| 84165 | <1% | 823 | $2K | |
| 82947 | <1% | 297 | $2K | |
| 88112 | <1% | 276 | $2K | |
| 99495 | <1% | 65 | $2K | |
| 82140 | <1% | 877 | $2K | |
| 0012A | <1% | 68 | $2K | |
| 86762 | <1% | 1,220 | $2K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 927 | $2K |
| 82731 | <1% | 679 | $2K | |
| 0154A | <1% | 92 | $2K | |
| 96380 | <1% | 129 | $2K | |
| 87106 | <1% | 666 | $2K | |
| 83521 | <1% | 281 | $2K | |
| 87640 | <1% | 419 | $2K | |
| 29105 | <1% | 38 | $2K | |
| 93270 | <1% | 188 | $2K | |
| 73521 | <1% | 89 | $2K | |
| 73060 | <1% | 229 | $2K | |
| 87075 | <1% | 1,339 | $2K | |
| 86592 | <1% | 760 | $2K | |
| 0074A | <1% | 82 | $2K | |
| 87102 | <1% | 602 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 30,001 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 47,999 | $2K |
| 99406 | <1% | 115 | $2K | |
| 83993 | <1% | 181 | $2K | |
| 85018 | <1% | 3,936 | $1K | |
| 86664 | <1% | 298 | $1K | |
| 86146 | <1% | 314 | $1K | |
| 77091 | <1% | 35 | $1K | |
| 82962 | <1% | 1,606 | $1K | |
| 88312 | <1% | 190 | $1K | |
| 86870 | <1% | 14 | $1K | |
| 88300 | <1% | 2,950 | $1K | |
| 0011A | <1% | 69 | $1K | |
| 86663 | <1% | 298 | $1K | |
| 84134 | <1% | 537 | $1K | |
| 86800 | <1% | 178 | $1K | |
| 86923 | <1% | 230 | $1K | |
| 82310 | <1% | 581 | $1K | |
| 87207 | <1% | 521 | $1K | |
| 87040 | <1% | 5,921 | $1K | |
| 90734 | <1% | 19 | $1K | |
| 88302 | <1% | 636 | $1K | |
| 72131 | <1% | 25 | $1K | |
| 81002 | <1% | 683 | $937.19 | |
| 86480 | <1% | 33 | $934.80 | |
| 76813 | <1% | 27 | $916.83 | |
| 94010 | <1% | 135 | $909.24 | |
| 97035 | <1% | 170 | $898.80 | |
| 0003A | <1% | 36 | $885.75 | |
| 86308 | <1% | 1,066 | $880.18 | |
| 97167 | <1% | 16 | $867.45 | |
| 96381 | <1% | 57 | $852.30 | |
| 90746 | <1% | 13 | $812.83 | |
| 90619 | <1% | 971 | $802.98 | |
| 85660 | <1% | 461 | $800.12 | |
| 90673 | <1% | 12 | $799.88 | |
| 87210 | <1% | 638 | $786.19 | |
| 97014 | <1% | 98 | $766.72 | |
| 82378 | <1% | 265 | $758.92 | |
| 0064U | <1% | 2,355 | $757.50 | |
| 12001 | <1% | 1,550 | $750.00 | |
| 85613 | <1% | 329 | $732.85 | |
| 84480 | <1% | 117 | $730.76 | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 423 | $695.05 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,207 | $689.96 |
| 84132 | <1% | 673 | $682.99 | |
| 92551 | <1% | 91 | $625.22 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,771 | $622.55 |
| 89230 | <1% | 24 | $606.65 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,968 | $598.23 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $572.68 |
| 73700 | <1% | 14 | $536.76 | |
| 0083A | <1% | 15 | $529.93 | |
| 0151A | <1% | 17 | $484.46 | |
| 12002 | <1% | 707 | $482.29 | |
| 82330 | <1% | 264 | $477.83 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 23,459 | $467.12 |
| 86580 | <1% | 61 | $462.02 | |
| 73620 | <1% | 55 | $429.86 | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 378 | $425.06 |
| 0064A | <1% | 18 | $412.05 | |
| 86593 | <1% | 160 | $366.20 | |
| 83605 | <1% | 8,441 | $348.28 | |
| 87088 | <1% | 89 | $323.57 | |
| 89051 | <1% | 1,043 | $319.56 | |
| 83010 | <1% | 156 | $312.74 | |
| 82010 | <1% | 1,673 | $282.92 | |
| 87338 | <1% | 31 | $281.08 | |
| 87015 | <1% | 340 | $250.03 | |
| 85670 | <1% | 200 | $249.29 | |
| 82040 | <1% | 147 | $235.22 | |
| 84681 | <1% | 26 | $231.61 | |
| 86705 | <1% | 37 | $206.24 | |
| 86901 | <1% | 14,366 | $176.49 | |
| 88142 | <1% | 16 | $176.31 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 3,221 | $146.51 |
| G0009 | Administration of pneumococcal vaccine | <1% | 115 | $145.52 |
| 86765 | <1% | 24 | $140.84 | |
| 86141 | <1% | 24 | $138.78 | |
| 92567 | <1% | 2,201 | $126.33 | |
| 12011 | <1% | 890 | $125.00 | |
| 76981 | <1% | 413 | $124.48 | |
| 82800 | <1% | 1,581 | $121.16 | |
| 80143 | <1% | 2,445 | $116.76 | |
| 72202 | <1% | 14 | $114.60 | |
| 87147 | <1% | 40 | $112.91 | |
| 83655 | <1% | 161 | $94.33 | |
| 86704 | <1% | 22 | $93.58 | |
| 96156 | <1% | 12 | $89.10 | |
| 92555 | <1% | 13 | $75.80 | |
| 88720 | <1% | 51 | $69.84 | |
| 88108 | <1% | 17 | $65.94 | |
| 80179 | <1% | 2,313 | $63.58 | |
| 95886 | <1% | 2,213 | $61.47 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,222 | $50.47 |
| 91319 | <1% | 182 | $48.02 | |
| 84478 | <1% | 15 | $47.64 | |
| 82805 | <1% | 56 | $45.24 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 34,175 | $43.95 |
| 86301 | <1% | 15 | $43.07 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 160 | $42.84 |
| 85384 | <1% | 28 | $37.94 | |
| 90461 | <1% | 2,927 | $37.61 | |
| 91318 | <1% | 260 | $35.86 | |
| 86703 | <1% | 14 | $34.44 | |
| 93325 | <1% | 3,978 | $33.07 | |
| 96376 | <1% | 9,506 | $30.69 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 39,374 | $29.26 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,615 | $27.18 |
| 69209 | <1% | 15 | $25.66 | |
| 93321 | <1% | 1,975 | $25.42 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 39,580 | $22.02 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 138 | $19.36 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 44,231 | $16.29 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 10,528 | $15.03 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 261 | $12.74 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 36,675 | $10.83 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 86 | $10.09 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 20,286 | $9.93 |
| 85460 | <1% | 16 | $8.72 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,104 | $8.14 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,058 | $7.39 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,222 | $7.21 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 33,526 | $6.56 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,469 | $6.24 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 11,180 | $3.28 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,171 | $2.56 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,784 | $1.84 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,587 | $1.45 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,417 | $1.29 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 5,528 | $1.07 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,505 | $0.68 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 4,592 | $0.09 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 424 | $0.00 |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 459 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 3,083 | $0.00 |
| 90715 | 0% | 8,477 | $0.00 | |
| 99173 | 0% | 660 | $0.00 | |
| 76942 | 0% | 233 | $0.00 | |
| 90633 | 0% | 2,409 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 4,838 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 4,501 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 1,539 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 2,777 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 422 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 924 | $0.00 |
| 94729 | 0% | 1,222 | $0.00 | |
| 90700 | 0% | 177 | $0.00 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 1,078 | $0.00 |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) | 0% | 568 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,911 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 38 | $0.00 |
| 90707 | 0% | 1,505 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 1,189 | $0.00 |
| 80305 | 0% | 108 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 820 | $0.00 |
| 90710 | 0% | 461 | $0.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 601 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 88 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 246 | $0.00 |
| 99188 | 0% | 595 | $0.00 | |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 0% | 36 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 98 | $0.00 |
| J1071 | Injection, testosterone cypionate, 1 mg | 0% | 36 | $0.00 |
| J1240 | Injection, dimenhydrinate, up to 50 mg | 0% | 94 | $0.00 |
| 90687 | 0% | 243 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 24 | $0.00 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0% | 42 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 125 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 66 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 99 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 243 | $0.00 |
| 88173 | 0% | 34 | $0.00 | |
| 90380 | 0% | 36 | $0.00 | |
| 77002 | 0% | 53 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 15 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 168 | $0.00 |
| L4387 | Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated, off-the-shelf | 0% | 61 | $0.00 |
| 64447 | 0% | 25 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 37 | $0.00 |
| 90685 | 0% | 47 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 28 | $0.00 |
| 76827 | 0% | 13 | $0.00 | |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 0% | 41 | $0.00 |
| 94664 | 0% | 27 | $0.00 | |
| 90713 | 0% | 29 | $0.00 | |
| C1769 | Guide wire | 0% | 1,179 | $0.00 |
| 88341 | 0% | 446 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 8,702 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 2,857 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 2,253 | $0.00 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 604 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 2,206 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 10,619 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 617 | $0.00 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 0% | 1,648 | $0.00 |
| 81050 | 0% | 198 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 308 | $0.00 |
| 90697 | 0% | 3,391 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 1,827 | $0.00 |
| 90696 | 0% | 712 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 360 | $0.00 |
| 88311 | 0% | 285 | $0.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 475 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 1,973 | $0.00 |
| 93320 | 0% | 1,226 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 847 | $0.00 |
| 90381 | 0% | 109 | $0.00 | |
| 90698 | 0% | 1,247 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 735 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 58 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 136 | $0.00 |
| 96368 | 0% | 532 | $0.00 | |
| 90680 | 0% | 3,221 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 890 | $0.00 |
| J3490 | Unclassified drugs | 0% | 426 | $0.00 |
| 36416 | 0% | 1,405 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 1,066 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 174 | $0.00 |
| 83883 | 0% | 41 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 193 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 421 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 126 | $0.00 |
| 95885 | 0% | 91 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 163 | $0.00 |
| 90632 | 0% | 29 | $0.00 | |
| 99174 | 0% | 186 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 12 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 46 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 27 | $0.00 |
| 0346T | 0% | 71 | $0.00 | |
| 64488 | 0% | 15 | $0.00 | |
| 82657 | 0% | 13 | $0.00 | |
| G0296 | Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) | 0% | 12 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 14 | $0.00 |
| 64415 | 0% | 15 | $0.00 | |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 22 | $0.00 |
| 77001 | 0% | 15 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 25 | $0.00 |
| 74420 | 0% | 13 | $0.00 | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | 0% | 26 | $0.00 |
| 87176 | 0% | 12 | $0.00 | |
| 87807 | 0% | 17 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 13 | $0.00 |
| 82438 | 0% | 12 | $0.00 | |
| 99459 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEAST, REBECCA (SVP, CFO)
Parent organizationBRONSON METHODIST HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Bronson Methodist Hospital | Kalamazoo, MI | $64.91M |
| Bronson Battle Creek Hospital | Battle Creek, MI | $43.89M |
| Bronson Lakeview Hospital | Paw Paw, MI | $15.63M |
| Bronson South Haven Hospital | South Haven, MI | $10.85M |
| Bronson Battle Creek Hospital | Battle Creek, MI | $9.80M |
| Bronson Lakeview Hospital | Paw Paw, MI | $6.57M |
| Bronson South Haven Hospital | South Haven, MI | $3.92M |
| Bronson at Home | Battle Creek, MI | $2.96M |
| Bronson Methodist Hospital | Kalamazoo, MI | $1.93M |
| Bronson South Haven Hospital | South Haven, MI | $704K |
| Bronson Lakeview Hospital | Decatur, MI | $563K |
| Bronson Lakeview Hospital | Bangor, MI | $530K |
| Bronson Lakeview Hospital | South Haven, MI | $134K |
| Bronson Lakeview Hospital | Paw Paw, MI | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.